Total Payments
$15,980
2024 Payments
$1,391
Companies
23
Transactions
92
Medicare Patients
2,804
Medicare Billing
$412,255
Payment Breakdown by Category
Research$8,009 (50.1%)
Food & Beverage$4,811 (30.1%)
Travel$3,024 (18.9%)
Education$135.60 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,009 | 16 | 50.1% |
| Food and Beverage | $4,811 | 57 | 30.1% |
| Travel and Lodging | $3,024 | 8 | 18.9% |
| Education | $135.60 | 11 | 0.8% |
Payments by Type
Research
$8,009
16 transactions
General
$7,971
76 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,021 | 14 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,833 | 17 | $0 (2023) |
| EMD Serono, Inc. | $1,283 | 10 | $0 (2019) |
| Hoffmann-La Roche Limited | $1,149 | 3 | $0 (2018) |
| Eli Lilly and Company | $717.40 | 2 | $0 (2022) |
| Genentech, Inc. | $696.15 | 9 | $0 (2024) |
| G1 Therapeutics, Inc. | $322.48 | 2 | $0 (2022) |
| Tolmar, Inc. | $292.34 | 2 | $0 (2023) |
| AstraZeneca UK Limited | $270.00 | 2 | $0 (2023) |
| ABBVIE INC. | $226.98 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,391 | 11 | Novartis Pharmaceuticals Corporation ($590.66) |
| 2023 | $2,623 | 22 | Merck Sharp & Dohme LLC ($1,716) |
| 2022 | $6,681 | 8 | NOVARTIS PHARMACEUTICALS CORPORATION ($5,820) |
| 2021 | $27.42 | 2 | PFIZER INC. ($15.50) |
| 2020 | $19.97 | 2 | PFIZER INC. ($19.97) |
| 2019 | $2,624 | 22 | EMD Serono, Inc. ($1,283) |
| 2018 | $1,979 | 11 | Hoffmann-La Roche Limited ($1,149) |
| 2017 | $633.91 | 14 | Merck Sharp & Dohme Corporation ($255.26) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $35.87 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | Genentech, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $139.17 | General |
| Category: BioOncology | ||||||
| 10/21/2024 | Genentech, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $60.35 | General |
| Category: BioOncology | ||||||
| 06/03/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $56.76 | General |
| 06/02/2024 | Genentech, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $37.31 | General |
| Category: BioOncology | ||||||
| 06/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 06/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Aveo Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $134.87 | General |
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $96.38 | Research |
| Study: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $563.47 | General |
| 03/26/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $104.45 | General |
| 12/07/2023 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $37.94 | General |
| 12/07/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Tolmar, Inc. | Leuprolide Acetate (Drug) | Food and Beverage | In-kind items and services | $146.17 | General |
| Category: Endocrine therapy in pre-menopausal women with HR+ & HER2-Negative breast cancer | ||||||
| 12/06/2023 | Tolmar, Inc. | — | Food and Beverage | In-kind items and services | $146.17 | General |
| 12/05/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 06/27/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 06/03/2023 | Genentech, Inc. | Lunsumio (Biological), Tecentriq | Food and Beverage | In-kind items and services | $36.36 | General |
| Category: BioOncology | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $65.87 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $26.47 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 06/02/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.39 | General |
| Category: Oncology | ||||||
| 04/20/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,820 | 1 |
| MS200647-0005 | EMD Serono, Inc. | $1,283 | 10 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $426.40 | 1 |
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $291.00 | 1 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ABBVIE INC. | $96.38 | 1 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | AbbVie Inc. | $92.34 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 613 | 1,390 | $296,429 | $96,349 |
| 2022 | 11 | 690 | 1,458 | $309,891 | $100,633 |
| 2021 | 13 | 764 | 1,730 | $366,398 | $127,632 |
| 2020 | 11 | 737 | 1,639 | $261,907 | $87,642 |
Total Patients
2,804
Total Services
6,217
Medicare Billing
$412,255
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 216 | 742 | $169,643 | $55,425 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 200 | 362 | $57,088 | $17,408 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 78 | $26,628 | $8,741 | 32.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,268 | $2,526 | 34.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 24 | $7,308 | $2,472 | 33.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 39 | $6,260 | $2,408 | 38.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $7,295 | $2,391 | 32.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 14 | $6,248 | $1,921 | 30.7% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 30 | 53 | $4,293 | $1,451 | 33.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 17 | $2,567 | $809.36 | 31.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 21 | $1,832 | $796.00 | 43.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 234 | 796 | $181,395 | $58,380 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 188 | 304 | $47,348 | $14,448 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 73 | $24,568 | $8,369 | 34.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 29 | 29 | $12,941 | $4,588 | 35.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $10,825 | $3,470 | 32.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 49 | $7,865 | $2,787 | 35.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 23 | $7,004 | $2,464 | 35.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $5,094 | $1,804 | 35.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 39 | 64 | $5,184 | $1,691 | 32.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 40 | 55 | $4,799 | $1,670 | 34.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 14 | 19 | $2,869 | $962.90 | 33.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 247 | 906 | $209,288 | $73,090 | 34.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 215 | 380 | $59,275 | $19,689 | 33.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 61 | 89 | $29,871 | $10,687 | 35.8% |
About Dr. Patrick Cobb, M.D
Dr. Patrick Cobb, M.D is a Hematology & Oncology healthcare provider based in Billings, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710968219.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Cobb, M.D has received a total of $15,980 in payments from pharmaceutical and medical device companies, with $1,391 received in 2024. These payments were reported across 92 transactions from 23 companies. The most common payment nature is "" ($8,009).
As a Medicare-enrolled provider, Cobb has provided services to 2,804 Medicare beneficiaries, totaling 6,217 services with total Medicare billing of $412,255. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Billings, MT
- Active Since 11/10/2005
- Last Updated 09/08/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710968219
Products in Payments
- KYMRIAH (Biological) $5,820
- MSB0011359C (Biological) $1,283
- TECENTRIQ (Biological) $1,149
- MK-7339 (Drug) $862.46
- COSELA (Drug) $322.48
- DARZALEX (Biological) $196.68
- KISQALI (Drug) $176.66
- Leuprolide Acetate (Drug) $146.17
- Columvi (Biological) $139.17
- KEYTRUDA (Drug) $130.85
- Lunsumio (Biological) $130.58
- ADCETRIS (Biological) $128.22
- ANDEXXA (Biological) $126.42
- PIQRAY (Drug) $119.31
- KEYTRUDA (Biological) $110.08
- ORENITRAM (Drug) $66.38
- Itovebi (Biological) $60.35
- OPDIVO (Biological) $56.50
- VOTRIENT (Drug) $40.47
- Tecentriq (Biological) $37.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Billings
Martin Lucas, M.d, M.D
Hematology & Oncology — Payments: $260.98
Hematology & Oncology $260.98
Roger Santala, Md, MD
Hematology & Oncology — Payments: $219.52
Hematology & Oncology $219.52
James Burke, Md, MD
Hematology & Oncology — Payments: $121.48
Hematology & Oncology $121.48
Troy Fiddler, M.d, M.D
Hematology & Oncology — Payments: $75.26
Hematology & Oncology $75.26
Brock Whittenberger, Md, MD
Hematology & Oncology — Payments: $25.05
Hematology & Oncology $25.05